Table 2

Baseline values and changes in the outcome variables during the one year of the study by treatment group2-150

Efficacy variableBaselineChange during the study
SASP n=68MTX n=69SASP+
MTX n=68
p valueSASP n=68MTX n=69SASP+
MTX n=69
p value
Symptomatic efficacy variable
Patient’s global assessment2.52.52.4NS−0.9−0.9−0.8NS
Physician’s global assessment2.42.42.4NS−0.7−0.7−0.6NS
Ritchie articular index17.616.518.9NS−7.1−4.2−9.40.001
Swollen joints10.59.49.4NS−4.5−3.9−4.5NS
Morning stiffness (min)789295NS−46−53−55NS
ESR (mm 1st h)424638NS−30−24−25NS
CRP (mg/l)303729NS−8−16−17NS
Structural efficacy variable
Erosion score2.773.784.28NS+2.38+2.38+1.85NS
Narrowing score3.344.524.63NS+2.26+2.12+1.61NS
Total damage score6.118.308.91NS+4.64+4.50+3.46NS
  • 2-150 Values given are mean and p value is referred to the statistical significance using the inter-group comparison (analysis of variance), in the intention to treat analysis. This analysis was performed in the completers with available radiographs (46, 49, and 49 patients in the SASP, MTX, and SASP + MTX groups, respectively).